NUT midline carcinoma of the head and neck: current perspectives
Open Access
- 1 April 2019
- journal article
- review article
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 12, 3235-3244
Abstract
NUT midline carcinoma (NMC) is a rare and aggressive subtype of squamous carcinoma that typically arises from midline supradiaphragmatic structures, frequently from the head and neck area. NMC is genetically driven by a chromosomal rearrangement involving the NUT gene, which forms oncoproteins considered major pathogenic drivers of cellular transformation. Diagnosis of NMC has been made remarkably easier with the availability of a commercial antibody against NUT, and can be established through positive nuclear immunohistochemical staining. Although NMC remains an underrecognized malignancy, in recent years there has appeared to be increasing awareness of disease and frequency of diagnosis in adults. To date, a standard treatment for head and neck NMC has not been established and a multimodal approach with systemic chemotherapy, surgery and radiation therapy is currently adopted in clinical practice. Recently, BET inhibitors and histone deacetylase inhibitors have emerged as two promising classes of targeted agents, currently investigated in clinical trials for adults with head and neck NMC. At the same time, combination approaches and novel targeted agents, such as next-generation BET inhibitors and CDK9 inhibitors, have shown preclinical activity. The present review explores the clinical pathological characteristics of NMC of the head and neck and presents the current state of the art on diagnosis, prognosis, and treatment of this rare but lethal disease.Keywords
This publication has 61 references indexed in Scilit:
- Structural Basis and Specificity of Acetylated Transcription Factor GATA1 Recognition by BET Family Bromodomain Protein Brd3Molecular and Cellular Biology, 2011
- Differentiation of NUT Midline Carcinoma by Epigenomic ReprogrammingCancer Research, 2011
- Selective inhibition of BET bromodomainsNature, 2010
- Oncogenesis by sequestration of CBP/p300 in transcriptionally inactive hyperacetylated chromatin domainsThe EMBO Journal, 2010
- NUT Gene Rearrangement in a Poorly-differentiated Carcinoma of the Submandibular GlandHead and Neck Pathology, 2010
- NUT Midline Carcinoma of the Parotid Gland With Mesenchymal DifferentiationAmerican Journal of Surgical Pathology, 2009
- Diagnosis of NUT Midline Carcinoma Using a NUT-specific Monoclonal AntibodyAmerican Journal of Surgical Pathology, 2009
- BRD–NUT oncoproteins: a family of closely related nuclear proteins that block epithelial differentiation and maintain the growth of carcinoma cellsOncogene, 2007
- Human cancers express a mutator phenotypeProceedings of the National Academy of Sciences, 2006
- Midline Carcinoma of Children and Young Adults With NUT RearrangementJournal of Clinical Oncology, 2004